Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ELA takes heart failure CRT (cardiac resynchronisation therapy) device to EU:

This article was originally published in Clinica

Executive Summary

ELA Medical, a Sorin Group company, has launched in Europe its ALTO 2 MSP 627 cardiac resynchronisation therapy (CRT) defibrillator for treating heart failure. The device, which complements ELA's CRT product line, incorporates therapies both for heart failure patients and for sudden cardiac death prevention, including ELA's proprietary PARAD/PARAD+ arrhythmia discrimination that identifies and analyses complex arrhythmias, and a fully configurable biventricular function with programmable ventricle-to-ventricle delay and independent left ventricular output.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel